usp2 catalytic domain Search Results


93
Bio-Techne corporation recombinant human his6-usp2 catalytic domain protein, cf
Recombinant Human His6 Usp2 Catalytic Domain Protein, Cf, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/usp2+catalytic+domain/bio-techne+corporation___e-506?v=Bio-Techne+corporation
Average 93 stars, based on 1 article reviews
recombinant human his6-usp2 catalytic domain protein, cf - by Bioz Stars, 2026-07
93/100 stars
  Buy from Supplier

94
R&D Systems e 322 human usp2 catalytic domain r d systems
E 322 Human Usp2 Catalytic Domain R D Systems, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/usp2+catalytic+domain/pm41270756-225-286-291?v=R%26D+Systems
Average 94 stars, based on 1 article reviews
e 322 human usp2 catalytic domain r d systems - by Bioz Stars, 2026-07
94/100 stars
  Buy from Supplier

94
R&D Systems recombinant usp2 catalytic domain
Recombinant Usp2 Catalytic Domain, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/usp2+catalytic+domain/pmc05940303-358-0-10?v=R%26D+Systems
Average 94 stars, based on 1 article reviews
recombinant usp2 catalytic domain - by Bioz Stars, 2026-07
94/100 stars
  Buy from Supplier

91
R&D Systems deubiquitinase usp2
PARK2 forms a phospho-ubiquitin-rich complex with VDAC. (A) FLAG-PARK2 and control cells were differentially labeled using SILAC. Equal amounts of mitochondria were mixed, solubilized and subjected to anti-FLAG immunoprecipitation, followed by native elution. Complexes from 2 independent experiments (with label switch) were resolved using BN-PAGE. Gel lanes were cut into equal slices, within the range of the 500-kDa complex, and each slice was analyzed by LC-MS. Shown are relative protein abundance ratios (FLAG-PARK2:control). (B) Solubilized mitochondria from FLAG-PARK2 cells treated with CCCP (3 h) were analyzed by 2D BN/SDS-PAGE, followed by western blotting. Asterisk indicates likely ubiquitinated forms of VDAC. (C) Anti-FLAG immunoprecipitations using mitochondria solubilized from FLAG-PARK2-expressing cells, treated with 10 μM CCCP, or with DMSO as a control, for 3 h. Solubilized mitochondria from COX6A1-FLAG-expressing cells were used as a specificity control.26 Eluates were analyzed by SDS-PAGE, followed by western blotting using antiserum for the indicated proteins. Total, 1%; Eluate, 100%. (D) Immunoprecipitated FLAG-PARK2 complexes from CCCP (3 h)-treated cells were analyzed by 2D gel analysis as in (B). Asterisk indicates likely ubiquitinated forms of VDAC. (E) Immunoprecipitated FLAG-PARK2 complexes from mitochondria, after CCCP or DMSO treatment of cells, were incubated with the <t>deubiquitinase</t> <t>USP2,</t> or the buffer control, for 1 h at 37°C. Samples were split and analyzed by BN-PAGE (right panel) and SDS-PAGE (left panel), followed by western blotting with the indicated antibodies. (F) Mitochondria from FLAG-PARK2 cells treated with CCCP for 3 h were solubilized in buffer containing 2% anti-VDAC serum or the respective pre-immune serum (control). Following solubilization, protein complexes were resolved by BN-PAGE analysis (4-13%) and were subsequently immunoblotted. (G) Mitochondria from wild-type cells treated with 10 µM CCCP, or DMSO control, for 3 h were solubilized and analyzed as in (B).
Deubiquitinase Usp2, supplied by R&D Systems, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/usp2+catalytic+domain/pmc05240832-278-1-6?v=R%26D+Systems
Average 91 stars, based on 1 article reviews
deubiquitinase usp2 - by Bioz Stars, 2026-07
91/100 stars
  Buy from Supplier

90
Boston Biochem catalytic domain of usp2
New transgenic Drosophila lines expressing non-cleavable, unanchored ubiquitin chains. ( A ) Amino acid sequence, abbreviation and purpose of HA-tagged ubiquitin chain transgenes. Neither chain can be conjugated onto another protein as it lacks a terminal “GG” motif that is required for isopeptide bond formation. Absence of internal “GG” motifs also ensures that they are not dismantled by DUBs . All lysine (K) residues within Ub 6 -Stop-K0 were mutated into the similar, but non-ubiquitinatable, amino acid arginine (R) to prevent ubiquitination. ( B ) Western blots from flies expressing the noted transgenes in all neurons (elav-Gal4, adult lysates), muscle cells (Mef-Gal4, adult lysates), or all glial cells (repo-Gal4, pharate adult lysates). Delta symbol (Δ): signal underneath the main band of lysine-less Ub 6 that we observe sometimes and could be a proteolytic fragment of the chain. ( C ) Western blots from stringently immunopurified, HA-tagged ubiquitin chains treated, or not, with the catalytic domain of <t>USP2</t> for the indicated amounts of time. Mef2-Gal4 flies were one day old. Flies with tub-Gal4-GS driver were induced to express Ub 6 for 7 days before being collected for protein extraction. ( D ) Western blots from soluble/pellet fractionation of flies expressing the noted ubiquitin chains in all muscle cells. Flies were one day old. The smear present in the Ub 6 -Stop-K0 samples comprises SDS-resistant species as a result of the buffer used in this protocol. As shown in C, second lane from the left and USP2 CD -treated lanes, similar smears from a different buffer and lysis protocol (Materials and Methods) are not collapsed by the addition of the DUB. Asterisks in panels: non-specific band detected by the anti-HA antibody.
Catalytic Domain Of Usp2, supplied by Boston Biochem, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/usp2+catalytic+domain/pmc07348737-64-36-39?v=Boston+Biochem
Average 90 stars, based on 1 article reviews
catalytic domain of usp2 - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier

90
Enzo Biochem usp2 catalytic domain
New transgenic Drosophila lines expressing non-cleavable, unanchored ubiquitin chains. ( A ) Amino acid sequence, abbreviation and purpose of HA-tagged ubiquitin chain transgenes. Neither chain can be conjugated onto another protein as it lacks a terminal “GG” motif that is required for isopeptide bond formation. Absence of internal “GG” motifs also ensures that they are not dismantled by DUBs . All lysine (K) residues within Ub 6 -Stop-K0 were mutated into the similar, but non-ubiquitinatable, amino acid arginine (R) to prevent ubiquitination. ( B ) Western blots from flies expressing the noted transgenes in all neurons (elav-Gal4, adult lysates), muscle cells (Mef-Gal4, adult lysates), or all glial cells (repo-Gal4, pharate adult lysates). Delta symbol (Δ): signal underneath the main band of lysine-less Ub 6 that we observe sometimes and could be a proteolytic fragment of the chain. ( C ) Western blots from stringently immunopurified, HA-tagged ubiquitin chains treated, or not, with the catalytic domain of <t>USP2</t> for the indicated amounts of time. Mef2-Gal4 flies were one day old. Flies with tub-Gal4-GS driver were induced to express Ub 6 for 7 days before being collected for protein extraction. ( D ) Western blots from soluble/pellet fractionation of flies expressing the noted ubiquitin chains in all muscle cells. Flies were one day old. The smear present in the Ub 6 -Stop-K0 samples comprises SDS-resistant species as a result of the buffer used in this protocol. As shown in C, second lane from the left and USP2 CD -treated lanes, similar smears from a different buffer and lysis protocol (Materials and Methods) are not collapsed by the addition of the DUB. Asterisks in panels: non-specific band detected by the anti-HA antibody.
Usp2 Catalytic Domain, supplied by Enzo Biochem, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/usp2+catalytic+domain/pmc04946925-184-65-69?v=Enzo+Biochem
Average 90 stars, based on 1 article reviews
usp2 catalytic domain - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier

90
Biomol GmbH usp2 catalytic domain uw9850
A, HeLa cells were treated±POH1 siRNA for 48 hours before incubation with 10 µg/ml cycloheximide. Cells were lysed and analysed by immunoblotting with ErbB2 29D8 and Ab20 antibodies, which recognize intracellular and extracellular epitopes of ErbB2 respectively, EGFR, and tubulin antibodies. B, quantitation shows that both EGFR (by antibody 1005) and ErbB2 (by antibodies Ab20 and 29D8) are turned over more rapidly in POH1 knock-down cells (data averaged from 3 experiments). C. HeLa cells were treated with four On Target Plus oligos (POH1) or with oligofectamine alone for 72 hours before lysis with hot lysis buffer. A higher molecular weight ErbB2 “smear” was observed in all 4 knock-down samples. D The high molecular weight smear associated with ErbB2 immuno-reactivity is sensitive to treatment with a deubiquitinase <t>(USP2).</t> HeLa cells were treated with POH1 siRNA or oligofectamine for 48 hours before lysis in the presence of NEM. ErbB2 was immunoprecipitated and treated in vitro with USP2 catalytic domain (100 nM, 8 hours, 37°C). Samples were analyzed by immunoblotting with ErbB2 antibodies targeting extracellular (Ab20) and intracellular (29D8) domains. Note that the smear detected with Ab20 is lost upon USP2 treatment whilst detection with the intracellular domain antibody increases. As a control for USP2 DUB-activity, EGFR was immunoprecipitated from EGF-stimulated (5 min) HeLa cells and treated in vitro with USP2 catalytic domain before SDS-PAGE and western blotting with anti-Ubiquitin.
Usp2 Catalytic Domain Uw9850, supplied by Biomol GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/usp2+catalytic+domain/pmc02677670-128-4-9?v=Biomol+GmbH
Average 90 stars, based on 1 article reviews
usp2 catalytic domain uw9850 - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier

90
Caltag-Medsystems ltd recombinant human usp2 catalytic domain, cf his tagged
DDI2 Cleaves Ubiquitylated NRF1 Protein In Vitro (A) Western blot analysis of NRF1 protein, isolated via GST-DSK2 chromatography, after treatment with DDI2, RAD23, and <t>USP2,</t> as indicated (4%–15% TGX). The mobility of NRF1 and cleaved NRF1 is shown on the right (see also arrow for cleaved NRF1). Zoomed-in images of lanes 13 and 14 and 19 and 20 are shown below. Note that large amounts of extract were used as input for GST-DSK2 purification, meaning that in relative terms, ~20× “extract equivalents” were loaded in lanes 5–20 compared to lanes 1–4. See also <xref ref-type=Figure S6 A. (B) Reprobing of the membrane from (A), with anti-ubiquitin antibodies. For simplicity, only the relevant lanes 5–9 are shown. (C) Experiment as in (A), but testing DDI2 D→N , as indicated. (D) As in (A) and (B), but testing cleavage of exogenously expressed, Myc-tagged versions of NRF1. N, normal NRF1 sequence. m, mutated sequence. Lower panel, lanes 2 and 6 are shown in the enlargement. The “dot” in lane 6 is not a cleavage band. See also independent experiment in Figure S6 B. " width="250" height="auto" />
Recombinant Human Usp2 Catalytic Domain, Cf His Tagged, supplied by Caltag-Medsystems ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/usp2+catalytic+domain/pmc07369636-24-0-9?v=Caltag-Medsystems+ltd
Average 90 stars, based on 1 article reviews
recombinant human usp2 catalytic domain, cf his tagged - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier

N/A
The Recombinant Human His6 USP2 Catalytic Domain Protein from R D Systems powered by Boston Biochem is derived from E coli The Recombinant Human His6 USP2 Catalytic Domain Protein has been validated for the following
  Buy from Supplier

N/A
The Recombinant Human USP2 Catalytic Domain Protein from R D Systems powered by Boston Biochem is derived from E coli The Recombinant Human USP2 Catalytic Domain Protein has been validated for the following applications Enzyme
  Buy from Supplier

Image Search Results


PARK2 forms a phospho-ubiquitin-rich complex with VDAC. (A) FLAG-PARK2 and control cells were differentially labeled using SILAC. Equal amounts of mitochondria were mixed, solubilized and subjected to anti-FLAG immunoprecipitation, followed by native elution. Complexes from 2 independent experiments (with label switch) were resolved using BN-PAGE. Gel lanes were cut into equal slices, within the range of the 500-kDa complex, and each slice was analyzed by LC-MS. Shown are relative protein abundance ratios (FLAG-PARK2:control). (B) Solubilized mitochondria from FLAG-PARK2 cells treated with CCCP (3 h) were analyzed by 2D BN/SDS-PAGE, followed by western blotting. Asterisk indicates likely ubiquitinated forms of VDAC. (C) Anti-FLAG immunoprecipitations using mitochondria solubilized from FLAG-PARK2-expressing cells, treated with 10 μM CCCP, or with DMSO as a control, for 3 h. Solubilized mitochondria from COX6A1-FLAG-expressing cells were used as a specificity control.26 Eluates were analyzed by SDS-PAGE, followed by western blotting using antiserum for the indicated proteins. Total, 1%; Eluate, 100%. (D) Immunoprecipitated FLAG-PARK2 complexes from CCCP (3 h)-treated cells were analyzed by 2D gel analysis as in (B). Asterisk indicates likely ubiquitinated forms of VDAC. (E) Immunoprecipitated FLAG-PARK2 complexes from mitochondria, after CCCP or DMSO treatment of cells, were incubated with the deubiquitinase USP2, or the buffer control, for 1 h at 37°C. Samples were split and analyzed by BN-PAGE (right panel) and SDS-PAGE (left panel), followed by western blotting with the indicated antibodies. (F) Mitochondria from FLAG-PARK2 cells treated with CCCP for 3 h were solubilized in buffer containing 2% anti-VDAC serum or the respective pre-immune serum (control). Following solubilization, protein complexes were resolved by BN-PAGE analysis (4-13%) and were subsequently immunoblotted. (G) Mitochondria from wild-type cells treated with 10 µM CCCP, or DMSO control, for 3 h were solubilized and analyzed as in (B).

Journal: Autophagy

Article Title: Phospho-ubiquitin-PARK2 complex as a marker for mitophagy defects

doi: 10.1080/15548627.2016.1254852

Figure Lengend Snippet: PARK2 forms a phospho-ubiquitin-rich complex with VDAC. (A) FLAG-PARK2 and control cells were differentially labeled using SILAC. Equal amounts of mitochondria were mixed, solubilized and subjected to anti-FLAG immunoprecipitation, followed by native elution. Complexes from 2 independent experiments (with label switch) were resolved using BN-PAGE. Gel lanes were cut into equal slices, within the range of the 500-kDa complex, and each slice was analyzed by LC-MS. Shown are relative protein abundance ratios (FLAG-PARK2:control). (B) Solubilized mitochondria from FLAG-PARK2 cells treated with CCCP (3 h) were analyzed by 2D BN/SDS-PAGE, followed by western blotting. Asterisk indicates likely ubiquitinated forms of VDAC. (C) Anti-FLAG immunoprecipitations using mitochondria solubilized from FLAG-PARK2-expressing cells, treated with 10 μM CCCP, or with DMSO as a control, for 3 h. Solubilized mitochondria from COX6A1-FLAG-expressing cells were used as a specificity control.26 Eluates were analyzed by SDS-PAGE, followed by western blotting using antiserum for the indicated proteins. Total, 1%; Eluate, 100%. (D) Immunoprecipitated FLAG-PARK2 complexes from CCCP (3 h)-treated cells were analyzed by 2D gel analysis as in (B). Asterisk indicates likely ubiquitinated forms of VDAC. (E) Immunoprecipitated FLAG-PARK2 complexes from mitochondria, after CCCP or DMSO treatment of cells, were incubated with the deubiquitinase USP2, or the buffer control, for 1 h at 37°C. Samples were split and analyzed by BN-PAGE (right panel) and SDS-PAGE (left panel), followed by western blotting with the indicated antibodies. (F) Mitochondria from FLAG-PARK2 cells treated with CCCP for 3 h were solubilized in buffer containing 2% anti-VDAC serum or the respective pre-immune serum (control). Following solubilization, protein complexes were resolved by BN-PAGE analysis (4-13%) and were subsequently immunoblotted. (G) Mitochondria from wild-type cells treated with 10 µM CCCP, or DMSO control, for 3 h were solubilized and analyzed as in (B).

Article Snippet: The deubiquitinase USP2 was purchased from BostonBiochem® (E-506).

Techniques: Labeling, Immunoprecipitation, Liquid Chromatography with Mass Spectroscopy, SDS Page, Western Blot, Expressing, Two-Dimensional Gel Electrophoresis, Incubation

New transgenic Drosophila lines expressing non-cleavable, unanchored ubiquitin chains. ( A ) Amino acid sequence, abbreviation and purpose of HA-tagged ubiquitin chain transgenes. Neither chain can be conjugated onto another protein as it lacks a terminal “GG” motif that is required for isopeptide bond formation. Absence of internal “GG” motifs also ensures that they are not dismantled by DUBs . All lysine (K) residues within Ub 6 -Stop-K0 were mutated into the similar, but non-ubiquitinatable, amino acid arginine (R) to prevent ubiquitination. ( B ) Western blots from flies expressing the noted transgenes in all neurons (elav-Gal4, adult lysates), muscle cells (Mef-Gal4, adult lysates), or all glial cells (repo-Gal4, pharate adult lysates). Delta symbol (Δ): signal underneath the main band of lysine-less Ub 6 that we observe sometimes and could be a proteolytic fragment of the chain. ( C ) Western blots from stringently immunopurified, HA-tagged ubiquitin chains treated, or not, with the catalytic domain of USP2 for the indicated amounts of time. Mef2-Gal4 flies were one day old. Flies with tub-Gal4-GS driver were induced to express Ub 6 for 7 days before being collected for protein extraction. ( D ) Western blots from soluble/pellet fractionation of flies expressing the noted ubiquitin chains in all muscle cells. Flies were one day old. The smear present in the Ub 6 -Stop-K0 samples comprises SDS-resistant species as a result of the buffer used in this protocol. As shown in C, second lane from the left and USP2 CD -treated lanes, similar smears from a different buffer and lysis protocol (Materials and Methods) are not collapsed by the addition of the DUB. Asterisks in panels: non-specific band detected by the anti-HA antibody.

Journal: Cells

Article Title: Isoleucine 44 Hydrophobic Patch Controls Toxicity of Unanchored, Linear Ubiquitin Chains through NF-κB Signaling

doi: 10.3390/cells9061519

Figure Lengend Snippet: New transgenic Drosophila lines expressing non-cleavable, unanchored ubiquitin chains. ( A ) Amino acid sequence, abbreviation and purpose of HA-tagged ubiquitin chain transgenes. Neither chain can be conjugated onto another protein as it lacks a terminal “GG” motif that is required for isopeptide bond formation. Absence of internal “GG” motifs also ensures that they are not dismantled by DUBs . All lysine (K) residues within Ub 6 -Stop-K0 were mutated into the similar, but non-ubiquitinatable, amino acid arginine (R) to prevent ubiquitination. ( B ) Western blots from flies expressing the noted transgenes in all neurons (elav-Gal4, adult lysates), muscle cells (Mef-Gal4, adult lysates), or all glial cells (repo-Gal4, pharate adult lysates). Delta symbol (Δ): signal underneath the main band of lysine-less Ub 6 that we observe sometimes and could be a proteolytic fragment of the chain. ( C ) Western blots from stringently immunopurified, HA-tagged ubiquitin chains treated, or not, with the catalytic domain of USP2 for the indicated amounts of time. Mef2-Gal4 flies were one day old. Flies with tub-Gal4-GS driver were induced to express Ub 6 for 7 days before being collected for protein extraction. ( D ) Western blots from soluble/pellet fractionation of flies expressing the noted ubiquitin chains in all muscle cells. Flies were one day old. The smear present in the Ub 6 -Stop-K0 samples comprises SDS-resistant species as a result of the buffer used in this protocol. As shown in C, second lane from the left and USP2 CD -treated lanes, similar smears from a different buffer and lysis protocol (Materials and Methods) are not collapsed by the addition of the DUB. Asterisks in panels: non-specific band detected by the anti-HA antibody.

Article Snippet: Beads were rinsed 10 times (including 2 × 5 min tumbling at 4 °C), and then split into two microfuge tubes and incubated at 37 °C with either NEM (0.5 mM) or the catalytic domain of USP2 (0.1 μM; Boston Biochem, Cambridge, MA, USA).

Techniques: Transgenic Assay, Expressing, Ubiquitin Proteomics, Sequencing, Western Blot, Protein Extraction, Fractionation, Lysis

A, HeLa cells were treated±POH1 siRNA for 48 hours before incubation with 10 µg/ml cycloheximide. Cells were lysed and analysed by immunoblotting with ErbB2 29D8 and Ab20 antibodies, which recognize intracellular and extracellular epitopes of ErbB2 respectively, EGFR, and tubulin antibodies. B, quantitation shows that both EGFR (by antibody 1005) and ErbB2 (by antibodies Ab20 and 29D8) are turned over more rapidly in POH1 knock-down cells (data averaged from 3 experiments). C. HeLa cells were treated with four On Target Plus oligos (POH1) or with oligofectamine alone for 72 hours before lysis with hot lysis buffer. A higher molecular weight ErbB2 “smear” was observed in all 4 knock-down samples. D The high molecular weight smear associated with ErbB2 immuno-reactivity is sensitive to treatment with a deubiquitinase (USP2). HeLa cells were treated with POH1 siRNA or oligofectamine for 48 hours before lysis in the presence of NEM. ErbB2 was immunoprecipitated and treated in vitro with USP2 catalytic domain (100 nM, 8 hours, 37°C). Samples were analyzed by immunoblotting with ErbB2 antibodies targeting extracellular (Ab20) and intracellular (29D8) domains. Note that the smear detected with Ab20 is lost upon USP2 treatment whilst detection with the intracellular domain antibody increases. As a control for USP2 DUB-activity, EGFR was immunoprecipitated from EGF-stimulated (5 min) HeLa cells and treated in vitro with USP2 catalytic domain before SDS-PAGE and western blotting with anti-Ubiquitin.

Journal: PLoS ONE

Article Title: Regulation of ErbB2 Receptor Status by the Proteasomal DUB POH1

doi: 10.1371/journal.pone.0005544

Figure Lengend Snippet: A, HeLa cells were treated±POH1 siRNA for 48 hours before incubation with 10 µg/ml cycloheximide. Cells were lysed and analysed by immunoblotting with ErbB2 29D8 and Ab20 antibodies, which recognize intracellular and extracellular epitopes of ErbB2 respectively, EGFR, and tubulin antibodies. B, quantitation shows that both EGFR (by antibody 1005) and ErbB2 (by antibodies Ab20 and 29D8) are turned over more rapidly in POH1 knock-down cells (data averaged from 3 experiments). C. HeLa cells were treated with four On Target Plus oligos (POH1) or with oligofectamine alone for 72 hours before lysis with hot lysis buffer. A higher molecular weight ErbB2 “smear” was observed in all 4 knock-down samples. D The high molecular weight smear associated with ErbB2 immuno-reactivity is sensitive to treatment with a deubiquitinase (USP2). HeLa cells were treated with POH1 siRNA or oligofectamine for 48 hours before lysis in the presence of NEM. ErbB2 was immunoprecipitated and treated in vitro with USP2 catalytic domain (100 nM, 8 hours, 37°C). Samples were analyzed by immunoblotting with ErbB2 antibodies targeting extracellular (Ab20) and intracellular (29D8) domains. Note that the smear detected with Ab20 is lost upon USP2 treatment whilst detection with the intracellular domain antibody increases. As a control for USP2 DUB-activity, EGFR was immunoprecipitated from EGF-stimulated (5 min) HeLa cells and treated in vitro with USP2 catalytic domain before SDS-PAGE and western blotting with anti-Ubiquitin.

Article Snippet: Samples with or without USP2 catalytic domain (100 nM; BIOMOL, UW9850) were incubated in a thermoshaker for 8 hours (37°C, 1000 rpm).

Techniques: Incubation, Western Blot, Quantitation Assay, Knockdown, Lysis, Molecular Weight, High Molecular Weight, Immunoprecipitation, In Vitro, Control, Activity Assay, SDS Page, Ubiquitin Proteomics

DDI2 Cleaves Ubiquitylated NRF1 Protein In Vitro (A) Western blot analysis of NRF1 protein, isolated via GST-DSK2 chromatography, after treatment with DDI2, RAD23, and USP2, as indicated (4%–15% TGX). The mobility of NRF1 and cleaved NRF1 is shown on the right (see also arrow for cleaved NRF1). Zoomed-in images of lanes 13 and 14 and 19 and 20 are shown below. Note that large amounts of extract were used as input for GST-DSK2 purification, meaning that in relative terms, ~20× “extract equivalents” were loaded in lanes 5–20 compared to lanes 1–4. See also <xref ref-type=Figure S6 A. (B) Reprobing of the membrane from (A), with anti-ubiquitin antibodies. For simplicity, only the relevant lanes 5–9 are shown. (C) Experiment as in (A), but testing DDI2 D→N , as indicated. (D) As in (A) and (B), but testing cleavage of exogenously expressed, Myc-tagged versions of NRF1. N, normal NRF1 sequence. m, mutated sequence. Lower panel, lanes 2 and 6 are shown in the enlargement. The “dot” in lane 6 is not a cleavage band. See also independent experiment in Figure S6 B. " width="100%" height="100%">

Journal: Molecular Cell

Article Title: DDI2 Is a Ubiquitin-Directed Endoprotease Responsible for Cleavage of Transcription Factor NRF1

doi: 10.1016/j.molcel.2020.05.035

Figure Lengend Snippet: DDI2 Cleaves Ubiquitylated NRF1 Protein In Vitro (A) Western blot analysis of NRF1 protein, isolated via GST-DSK2 chromatography, after treatment with DDI2, RAD23, and USP2, as indicated (4%–15% TGX). The mobility of NRF1 and cleaved NRF1 is shown on the right (see also arrow for cleaved NRF1). Zoomed-in images of lanes 13 and 14 and 19 and 20 are shown below. Note that large amounts of extract were used as input for GST-DSK2 purification, meaning that in relative terms, ~20× “extract equivalents” were loaded in lanes 5–20 compared to lanes 1–4. See also Figure S6 A. (B) Reprobing of the membrane from (A), with anti-ubiquitin antibodies. For simplicity, only the relevant lanes 5–9 are shown. (C) Experiment as in (A), but testing DDI2 D→N , as indicated. (D) As in (A) and (B), but testing cleavage of exogenously expressed, Myc-tagged versions of NRF1. N, normal NRF1 sequence. m, mutated sequence. Lower panel, lanes 2 and 6 are shown in the enlargement. The “dot” in lane 6 is not a cleavage band. See also independent experiment in Figure S6 B.

Article Snippet: Recombinant Human USP2 Catalytic Domain, CF His tagged , CALTAG Medsystems LTD , Cat# AG-40T-0539-C050.

Techniques: In Vitro, Western Blot, Isolation, Chromatography, Purification, Sequencing

DDI2 Fails to Cleave Purified Ubiquitin Chains but Preferentially Binds and Cleaves Slowly Migrating Ubiquitylated Species (A) Coomassie-stained gels of different commercially available ubiquitin chains before and after incubation with DDI2, RAD23, or the catalytic domain of USP2, as indicated. Untreated substrates are indicated by stippled boxes. Note that USP2 cleaves all these chains to mono- or di-ubiquitin. See also lack of detectable mono-/di-ubiquitin in the blot of <xref ref-type=Figure S5 D. (B) Schematic of experiments in (C) and (D). (C) Western blot analysis of ubiquitylated proteins in bound and unbound (supernatant) fractions after incubation with chemically inactivated DDI2 protein (note that two biological replicates of the same experiment are shown; lanes 1 and 2/5 and 6 and lanes 3 and 4/7 and 8). Note the specific depletion of slowly migrating ubiquitylated proteins in lanes 1 and 3 and the enrichment of the same in lanes 5 and 7. (D) As in (C), but ubiquitylated proteins on FLAG-DDI2 D→N beads, incubated with DDI2 or DDI2 D→N (non-FLAG tagged to avoid non-specific “displacement” from the beads), as indicated. Note the disappearance of ubiquitylated proteins from beads after incubation with WT DDI2 (above black stippled line, lane 3) and concomitant release of faster-migrating ubiquitylated proteins into the supernatant (below red stippled line, lane 9). See also ImageJ scanning traces below, with position of stippled lines indicated for reference. Please note that the exposure time of the blot on the right is longer than that on the left; only small amounts DDI2-bound material can be eluted. See also Figure S5 . " width="100%" height="100%">

Journal: Molecular Cell

Article Title: DDI2 Is a Ubiquitin-Directed Endoprotease Responsible for Cleavage of Transcription Factor NRF1

doi: 10.1016/j.molcel.2020.05.035

Figure Lengend Snippet: DDI2 Fails to Cleave Purified Ubiquitin Chains but Preferentially Binds and Cleaves Slowly Migrating Ubiquitylated Species (A) Coomassie-stained gels of different commercially available ubiquitin chains before and after incubation with DDI2, RAD23, or the catalytic domain of USP2, as indicated. Untreated substrates are indicated by stippled boxes. Note that USP2 cleaves all these chains to mono- or di-ubiquitin. See also lack of detectable mono-/di-ubiquitin in the blot of Figure S5 D. (B) Schematic of experiments in (C) and (D). (C) Western blot analysis of ubiquitylated proteins in bound and unbound (supernatant) fractions after incubation with chemically inactivated DDI2 protein (note that two biological replicates of the same experiment are shown; lanes 1 and 2/5 and 6 and lanes 3 and 4/7 and 8). Note the specific depletion of slowly migrating ubiquitylated proteins in lanes 1 and 3 and the enrichment of the same in lanes 5 and 7. (D) As in (C), but ubiquitylated proteins on FLAG-DDI2 D→N beads, incubated with DDI2 or DDI2 D→N (non-FLAG tagged to avoid non-specific “displacement” from the beads), as indicated. Note the disappearance of ubiquitylated proteins from beads after incubation with WT DDI2 (above black stippled line, lane 3) and concomitant release of faster-migrating ubiquitylated proteins into the supernatant (below red stippled line, lane 9). See also ImageJ scanning traces below, with position of stippled lines indicated for reference. Please note that the exposure time of the blot on the right is longer than that on the left; only small amounts DDI2-bound material can be eluted. See also Figure S5 .

Article Snippet: Recombinant Human USP2 Catalytic Domain, CF His tagged , CALTAG Medsystems LTD , Cat# AG-40T-0539-C050.

Techniques: Purification, Staining, Incubation, Western Blot

Journal: Molecular Cell

Article Title: DDI2 Is a Ubiquitin-Directed Endoprotease Responsible for Cleavage of Transcription Factor NRF1

doi: 10.1016/j.molcel.2020.05.035

Figure Lengend Snippet:

Article Snippet: Recombinant Human USP2 Catalytic Domain, CF His tagged , CALTAG Medsystems LTD , Cat# AG-40T-0539-C050.

Techniques: Recombinant, Mass Spectrometry, Western Blot, Sequencing, Plasmid Preparation, Software, Transfection